Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLSNASDAQ:ARWRNASDAQ:MIRMNASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$19.44+1.6%$18.82$16.10▼$43.76$2.44B0.732.26 million shs384,417 shsARWRArrowhead Pharmaceuticals$16.91+3.1%$13.44$9.57▼$30.41$2.34B0.891.92 million shs315,112 shsMIRMMirum Pharmaceuticals$45.44-1.2%$42.62$24.07▼$54.23$2.25B0.95477,779 shs64,144 shsMNMDMind Medicine (MindMed)$7.76+3.7%$6.26$4.70▼$10.44$586.29M2.521.64 million shs313,374 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+13.19%+9.75%-5.90%-23.59%-51.24%ARWRArrowhead Pharmaceuticals+2.12%+8.39%+13.73%-4.15%-28.54%MIRMMirum Pharmaceuticals+3.68%+4.48%+5.22%+1.66%+91.30%MNMDMind Medicine (MindMed)+3.89%+2.47%+7.94%+20.06%-15.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.5682 of 5 stars4.32.00.04.43.22.50.6ARWRArrowhead Pharmaceuticals3.571 of 5 stars3.32.00.03.42.12.50.0MIRMMirum Pharmaceuticals3.809 of 5 stars3.60.00.04.22.52.50.6MNMDMind Medicine (MindMed)1.6999 of 5 stars3.61.00.00.01.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.62Moderate Buy$40.05106.03% UpsideARWRArrowhead Pharmaceuticals 2.67Moderate Buy$42.13149.11% UpsideMIRMMirum Pharmaceuticals 3.17Buy$60.7333.64% UpsideMNMDMind Medicine (MindMed) 3.25Buy$25.11223.60% UpsideCurrent Analyst Ratings BreakdownLatest MNMD, APLS, MIRM, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025APLSApellis PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$775.84M3.15N/AN/A$1.64 per share11.85ARWRArrowhead Pharmaceuticals$545.21M4.28N/AN/A$1.54 per share10.98MIRMMirum Pharmaceuticals$379.25M5.94N/AN/A$5.33 per share8.53MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$528.63M-$1.79N/AN/AN/A-34.97%-103.11%-28.96%7/30/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/14/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.61N/AN/AN/A-31.69%-41.22%-14.81%8/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%8/12/2025 (Estimated)Latest MNMD, APLS, MIRM, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals1.914.363.73ARWRArrowhead Pharmaceuticals7.276.096.09MIRMMirum Pharmaceuticals1.333.343.15MNMDMind Medicine (MindMed)0.099.009.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%ARWRArrowhead Pharmaceuticals62.61%MIRMMirum PharmaceuticalsN/AMNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%ARWRArrowhead Pharmaceuticals4.30%MIRMMirum Pharmaceuticals14.36%MNMDMind Medicine (MindMed)2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770125.68 million115.93 millionOptionableARWRArrowhead Pharmaceuticals400138.10 million120.68 millionOptionableMIRMMirum Pharmaceuticals14049.54 million37.03 millionOptionableMNMDMind Medicine (MindMed)4075.55 million71.68 millionOptionableMNMD, APLS, MIRM, and ARWR HeadlinesRecent News About These CompaniesWall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to TradeJune 2 at 11:01 AM | zacks.comMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerMay 27, 2025 | finance.yahoo.comHC Wainwright Issues Pessimistic Forecast for MNMD EarningsMay 27, 2025 | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of MNMD Q3 EarningsMay 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for MNMD Q1 Earnings?May 25, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of MNMD FY2025 EarningsMay 25, 2025 | marketbeat.comCantor Fitzgerald Analysts Cut Earnings Estimates for MNMDMay 25, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for MNMD Q1 Earnings?May 25, 2025 | americanbankingnews.comNorthern Trust Corp Has $4.77 Million Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 24, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Acquired by AWM Investment Company Inc.May 23, 2025 | marketbeat.comTang Capital Management LLC Acquires New Shares in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 20, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsMay 19, 2025 | businesswire.comCantor Fitzgerald Upgrades Mind Medicine (MindMed) (NASDAQ:MNMD) to "Strong-Buy"May 17, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by AnalystsMay 17, 2025 | marketbeat.comCantor Fitzgerald Forecasts MNMD FY2025 EarningsMay 16, 2025 | marketbeat.comDoes Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?May 13, 2025 | zacks.comWhy Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%May 12, 2025 | aaii.comChardan Capital Reaffirms "Buy" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD)May 11, 2025 | marketbeat.comDriehaus Capital Management LLC Cuts Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 11, 2025 | marketbeat.comEarnings call transcript: MindMed Q1 2025 results show mixed signalsMay 10, 2025 | uk.investing.comDeep Track Capital LP Has $19.60 Million Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNMD, APLS, MIRM, and ARWR Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$19.44 +0.30 (+1.57%) As of 11:10 AM EasternApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$16.91 +0.51 (+3.11%) As of 11:10 AM EasternArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Mirum Pharmaceuticals NASDAQ:MIRM$45.44 -0.53 (-1.15%) As of 11:10 AM EasternMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Mind Medicine (MindMed) NASDAQ:MNMD$7.76 +0.28 (+3.74%) As of 11:10 AM EasternMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
